X4 Pharmaceuticals (XFOR) investor relations material

Executive summary

• Focused on developing and commercializing therapeutics for rare hematology diseases, with XOLREMDI (mavorixafor) as the lead product approved in the US and EU for WHIM syndrome.

• Progressing the pivotal Phase 3 4WARD trial for chronic neutropenia, with enrollment and FDA discussions ongoing.

• Completed transfer of EU marketing authorization for XOLREMDI to Norgine following regulatory approval.

Financial highlights

• Total revenue for Q2 2026 was $8.8M, up from $2.0M in Q2 2025; six-month revenue was $11.5M, down from $30.8M due to prior year one-time license revenue.

• Net product sales grew to $2.4M in Q2 2026 from $1.7M in Q2 2025, driven by increased patient prescriptions.

• Net loss for Q2 2026 was $16.2M, improved from $25.7M in Q2 2025; six-month net loss was $36.4M.

• Operating expenses decreased year-over-year due to prior restructuring and lower G&A costs.

• Cash, cash equivalents, and marketable securities totaled $208.0M as of June 30, 2026.

Outlook and guidance

• Current cash and equivalents expected to fund operations and debt obligations for at least the next 12 months.

• Additional capital will be needed to fund operations beyond this period; future funding may come from equity, debt, or partnerships.

• Ongoing focus on completing the 4WARD trial and expanding XOLREMDI's market presence.